Altered Bone Mineral Density in Patients with Complete Androgen Insensitivity Syndrome

@article{Bertelloni1998AlteredBM,
  title={Altered Bone Mineral Density in Patients with Complete Androgen Insensitivity Syndrome},
  author={Silvano Bertelloni and Giampiero I. Baroncelli and Giovanni Federico and Marco Cappa and Roberto Lala and Giuseppe Saggese},
  journal={Hormone Research in Paediatrics},
  year={1998},
  volume={50},
  pages={309 - 314}
}
Androgens have major influences on the regulation of bone mineralization. Because of their unique peripheral metabolism androgens may act on bone via activation of the androgen and/or estrogen receptor. Patients with complete androgen insensitivity syndrome (cAIS) are natural models to assess androgen actions on bone. We studied bone mineral density (BMD) in 10 patients with cAIS (mean age 13.70, range 4.7–19.8 years); 3 patients were studied before gonadectomy; the others were castrated and 6… 

Figures and Tables from this paper

Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes.

1) Androgens are of direct importance in the development and/or maintenance of BMD; and 2) testosterone and/ or low levels of dihydrotestosterone appear to be sufficient for BMD development and-or maintenance.

Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene

Data suggest an important role for androgens in normal male growth and bone density not replaced by estrogens in patients with AIS with mutations in the androgen receptor (AR) gene.

Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads

The maintenance of testes may represent a strategy to improve bone health in women with CAIS, but a strict follow-up to monitor the cancer risk is mandatory mainly from their 20s onwards.

The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome.

It is concluded that even when compliance to exogenous estrogen use is excellent, women with complete AIS show moderate deficits in spine BMD, averaging close to 1 SD from normative means, and that with correction of BMD for bone size, skeletal deficits are magnified and include the proximal femur.

Case Report: Low Bone and Normal Lean Mass in Adolescents With Complete Androgen Insensitivity Syndrome

These limited data indicate that adolescents with CAIS have bone mass deficit, and further studies are needed to understand the extent of BMD abnormalities and the effect of gonadectomy, especially early in childhood, and to establish the optimal HRT regimen for bone accrual.

Bone mineral density, body composition and metabolic profiles in adult women with complete androgen insensitivity syndrome and removed gonads using oral or transdermal estrogens.

The results reinforce the importance of adequate hormonal treatment in women living with CAIS, suggesting a better effect from the transdermal route over the oral route.

Dilemmas in management of osteoporosis in patients with complete androgen insensitivity syndrome

The objective is to report a patient with CAIS status post prepubertal orchiectomy that developed early osteoporosis and to describe the lack of optimal strategies and consensus available to improve bone health in this population.

Anthropometric, metabolic and bone changes in women with premature ovarian failure when using estradiol analogues

The preliminary data suggest that estradiol is administered both transdermally and orally in young women with hypergonadotropic amenorrhea, with a significant time-treatment interaction effect.
...

References

SHOWING 1-10 OF 43 REFERENCES

Androgen-Receptor Blockade Does Not Impair Bone Mineral Density in Adolescent Females

It is concluded that in adolescent women, peripheral hyperandrogenism is not associated with abnormal BMD; long-term treatment with flutamide, which blocks the androgen receptor, does not alter their BMD.

Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

Bone density increases during gonadal steroid replacement of GnRH-deficient men, particularly in men who are skeletally immature, and neither cortical nor trabecular bone density returned to normal levels.

Short‐term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty

It is concluded that boys with constitutional delay of puberty have reduced BMC and BMD and the delay in statural and bone ages did not totally account for the decreased bone mass.

Flutamide‐mediated androgen blockade evokes osteopenia in the female rat

  • A. GouldingE. Gold
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1993
Findings support the view that androgens play an important role in preserving bone mass in the female rat, and it seems possible that antiandrogen drugs cause osteopenia in people as well as in the rat.

Androgens and bone.

Observations in androgen-resistant animals clearly demonstrated that the sexual dimorphism of bone depends on the presence of a functional androgen receptor, and optimal peak bone mass seems related to an appropriately timed androgen secretion.

Bone and mineral metabolism in the androgen‐resistant (testicular feminized) male rat

It is concluded that the absence of functional androgen receptors results in a decrease in radial and longitudinal bone growth and in a decreases in serum IGF‐I concentrations.

Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls.

It is concluded that in normal girls, the pubertal growth spurt also results from the action of estrogens rather than of adrenal androgens, and physiologic estrogen replacement in hypogonadal females should be started at a bone age of about 11 years, and should not be delayed in the hope of achieving a greater mature height.

Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.

Nandrolone decanoate therapy increases bone formation, and the difference in the time-weighted mean rates of change between the two groups was significant.

Bone mineral homeostasis, bone growth, and mineralisation during years of pubertal growth: a unifying concept.

A unifying concept places growth hormone in the unique position of being the main driver and co-ordinator during childhood and adolescence of bone growth an mineralisation on the one hand, and of blood mineral homeostasis on the other.